Antibody response to VZV vaccination in HIV infected children

Ołdakowska, Agnieszka; Coupland, Urszula; Dobosz, Sabina; Popielska, Jolanta; Szczepańska-Putz, Małgorzata; Marczyńska, Magdalena

doi:10.1016/j.hivar.2015.03.004

Cited by 4 publications

(8 citation statements)

References 12 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seventy-one studies fulfilled the eligibility criteria (Supplementary data 4). Twenty-eight studies reported on safety [24], [25], [29], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61] and 62 reported on immunogenicity [23], [24], [25], [29], [30], [33], [34], [35], [36], [37], [39], [40], [41], [43], [44], [45], [47], [48], [50], [51], [53], [55], [56], [57], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87], …”

Section: Resultsmentioning

confidence: 99%

Safety and Immunogenicity of Measles Vaccination in HIV-Infected and HIV-Exposed Uninfected Children: A Systematic Review and Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

Background HIV-infected and HIV-exposed uninfected (HEU) children have an increased risk of measles that may be due to altered immune responses or suboptimal timing of measles vaccination. We aimed to evaluate the safety and immunogenicity of measles vaccination in HIV-infected and HEU children. Methods For this systematic review and meta-analysis, we searched PubMed, Embase, Cochrane Library, CINAHL, Global Health Library and IndMED on May 9, 2018. Studies were included if they reported on safety or seroresponse (either seroprotection/seropositivity/seroconversion) after measles vaccination in HIV-infected or HEU children. We calculated pooled estimates to compare immunogenicity outcomes between HIV-infected, HEU and HIV-unexposed children, using risk ratios [RRs] (with 95%CIs). PROSPERO registration number: CRD42017057411. Findings Seventy-one studies met the inclusion criteria (15,363 children). Twenty-eight studies reported on safety; vaccine-associated adverse events and deaths were uncommon. Sixty-two studies reported on immunogenicity, 27 were included in the meta-analysis. HIV-infected children had lower seroresponse rates after primary vaccination compared with HIV-unexposed (RR 0.74; 95%CI: 0.61–0.90, I 2 = 85.9%) and HEU children (0.78; 0.69–0.88, I 2 = 77.1%), which was mitigated by antiretroviral therapy and time interval between vaccination and serology. HEU and HIV-unexposed children had similar seroresponses. Vaccination at 6-months resulted in similar proportions of HIV-infected children having seroresponse compared with HIV-unexposed (0.96; 0.77–1.19) and HEU children (1.00; 0.73–1.37, I 2 = 63.7%). Interpretation Primary measles vaccination at 6-months of age may provide protection against measles during early infancy in settings with high prevalence of maternal HIV-infection, however, further studies are needed to evaluate this strategy in HEU children and HIV-infected children receiving antiretroviral therapy. Funding South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation in Vaccine Preventable Diseases; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit.

show abstract

Section: Resultsmentioning

confidence: 99%

Safety and Immunogenicity of Measles Vaccination in HIV-Infected and HIV-Exposed Uninfected Children: A Systematic Review and Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The vaccine should be given whether the child is HIV-infected or not. 35,36 The vaccine is less effective in HIVinfected infants than in the general population, but early treatment with antiretroviral drugs can increase its effectiveness.…”

Section: Measles Vaccinementioning

confidence: 99%

Measles virus

Naim

2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Only four studies reported seroconversion and/or GMT levels stratified by HIV disease stage (CD4-cell counts, 81,82 CD4 cell count percentages/fraction, 62 plasma viral suppression 51 ) or ART status 52,53 (Supplement Figure S6A-D, supplement table S11). One trial reported high GMT titers at 28 weeks for PLHIV in any CD4-cell counts subgroups although GMT titers and the proportion that seroconverted following vaccination were lower for PLHIV with CD4 ≤200 (HPV-16, HPV-18, HPV-6, HPV-11: 0.93, 0.75, 0.84, 0.92 if CD4 ≤200 cells/mL and 0.99, 0.91, 0.96, 0.98 if >350 cells/mL, respectively, N s =2, Supplement S3).…”

Section: Immunogenicity Results -By Hiv Status or Disease Stagementioning

confidence: 99%

“…One trial reported high GMT titers at 28 weeks for PLHIV in any CD4-cell counts subgroups although GMT titers and the proportion that seroconverted following vaccination were lower for PLHIV with CD4 ≤200 (HPV-16, HPV-18, HPV-6, HPV-11: 0.93, 0.75, 0.84, 0.92 if CD4 ≤200 cells/mL and 0.99, 0.91, 0.96, 0.98 if >350 cells/mL, respectively, N s =2, Supplement S3). 81,82 A second trial reported a positive and significant correlation between high CD4% and antibody titers but did not provide stratified estimates 63 whereas a third trial found no difference in antibody titers by CD4% nadir 62 (Supplement Figure S6A-D). Finally, a fourth trial reported higher seropositivity rates and antibody titers in PLHIV on ART than not on ART 52,53 while another one reported higher antibody titers for all four HPV vaccine types among PLHIV virally suppressed compared to non-suppressed.…”

Section: Immunogenicity Results -By Hiv Status or Disease Stagementioning

confidence: 99%